Contact this trialFirst, we need to learn more about you.
PD-L1 Inhibitor
Cabozantinib + Atezolizumab for Bladder Cancer
Recruiting1 awardPhase 2
Hackensack, New Jersey
This trial is testing whether a combination of two drugs, cabozantinib and atezolizumab, is effective in treating patients with urothelial carcinoma who are ineligible for or decline cisplatin-based therapy.
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service.
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.
By clicking start, you agree to our
terms of service